logo

Aim Immunotech Inc. (AIM)



Trade AIM now with
  Date
  Headline
12/24/2020 10:11:48 AM AIM ImmunoTech Announces Availability Of ME/CFS Trial Of Its Drug Ampligen For Enrollment To COVID-19 ‘Long Haulers’
12/21/2020 6:48:10 AM AIM ImmunoTech Says FDA Grants Orphan Drug Designation Status To Ampligen For Pancreatic Cancer
11/25/2020 6:52:37 AM AIM ImmunoTech Announces Developments In Work To Develop New Treatments Or Preventive Strategies For COVID-19
10/6/2020 9:05:40 AM AIM ImmunoTech Announces IRB Approval To Enroll COVID-19 ‘Long Haulers’ In AMP-511 ME/CFS Clinical Trial Of Ampligen
8/15/2019 6:48:16 AM Hemispherx Biopharma Q2 Net Loss From Cont Ops $2.03 Mln Or $1.07 Per Share
5/31/2019 10:41:19 AM Hemispherx Biopharma Approves 1-for-44 Reverse Stock Split
1/2/2019 8:32:32 AM Hemispherx Announces Advancement In Expanded Access Program For Ampligen
12/26/2018 8:31:57 AM Hemispherx Says Works With Apple, Affected Parties For Solution To Correct Apple IOS12 Stocks Application Misinformation
12/19/2018 8:33:32 AM Hemispherx Biopharma Reports First Large Ampligen Shipment To Clinical Site For Use In US Expanded Access Program
12/12/2018 8:33:01 AM Hemispherx Biopharma Issues Letter To Stockholders
11/15/2018 9:05:33 AM Hemispherx Biopharma Q3 Net Loss From Cont Ops $3.078 Mln Or $0.07 Per Share
10/22/2018 8:32:00 AM Hemispherx Outlines Ampligen Combination Therapy Clinical Study Strategy For Multiple Cancers In Letter To Stockholders